Key facts
- It has raised $18.9M; the latest was Later Stage VC ($6.0M) in Jul 2024.
- Notable investors include Viola Ventures, Awz Ventures, D Capital Partners, Elcam Medical, Giora Kaplan — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for NanoPass Technologies
- ·The full record, as it builds
Funding rounds
No funding rounds for NanoPass Technologies are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About NanoPass Technologies
Developer of micro-needles intended to deliver intradermal and cosmetic enhancement. The company's developed needle commercializes painless intradermal (skin) delivery alternatives for vaccines and large molecules, it is expanding its reach and forging partnerships with leading researchers, physicians, pharmaceutical companies, and distributors to advance patient care worldwide and also provides intradermal delivery solutions for vaccines, aesthetics, and drugs, while pioneering virtually pain-free administration methods, enabling clinicians to inject drugs, proteins, and vaccines into the skin of the patients with ease.
- Sector
- Healthcare
- HQ
- Nes Ziona, Israel
- Founded
- 2000
- Employees
- 17
- Website
- nanopass.com/
- Ownership
- Privately Held (backing)
NanoPass Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in NanoPass Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on NanoPass Technologies in its N-PORT filings yet. We sweep new filings monthly.